Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Toluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | ACP3 | P15309 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL437383 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL5806354 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL10856877 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL28555681 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL27269290 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL1011089 | 1.00 | LMNA (0.65) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL1931900 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL3630619 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL27955550 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 | |
| Toluene SCHEMBL29009365 | 0.97 | LMNA (0.61) | LMNATSHRALOX12ACHEACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | claimed |
| EP-0167204-A1 | Method for improving the absorption and effectiveness of a catecholamine compound | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1986-01-08 | — | — | EP | claimed |
| CN-113661213-B | Resin composition, prepreg, laminated board, multilayer printed wiring board, and semiconductor package | 株式会社力森诺科 | 2025-04-08 | — | — | CN | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-6797678-B2 | OBTAINED BY HEATING AN ACIDIC PHOSPHATE ESTER AND/OR A PHOSPHITE ESTER AND AN IMIDE-BASED DISPERSANT (SUCH AS POLYBUTENYL SUCCINIMIDE) CONTAINING BORON; WEAR RESISTANCE, SCORING RESISTANCE AND PROLONGS SURFACE FATIGUE LIFE | IDEMITSU KOSAN CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20020165102-A1 | Lubricating oil composition for cellulose base wet friction material | IDEMITSU KOSAN CO., LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-20020055441-A1 | Lubricant additive | IDEMITSU KOSAN CO., LTD. (JP) | 2002-05-09 | — | — | US | disclosed |
| US-6352962-B1 | ADDITIVE FOR TRACTION DRIVE FLUID OBTAINED BY HEATING AT LEAST ONE ESTER SELECTED FROM ACIDIC PHOSPHATE ESTER AND PHOSPHITE ESTER AND SUCCINIMIDE DISPERSANT CONTAINING BORON AT TEMPERATURE OF 120 TO 150 DEGREES C. FOR 5 HOURS OR MORE | IDEMITSU KOSAN CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6303546-B1 | CONTAINING PHOSPHATE ESTER, BORON-CONTAINING IMIDE BASE DISPERSANT AND BORON-FREE IMIDE BASE DISPERSANT | IDEMITSU KOSAN CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| EP-1142983-A1 | Lubricant additive | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1057884-A1 | Traction drive fluid | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1057882-A1 | Lubricating oil composition for cellulose base wet friction material | IDEMITSU KOSAN CO., LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | LMNA 857/4885TSHR 3152/4885ALOX12 1523/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | LMNA 4198/4885TSHR 4136/4885ALOX12 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.